Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study Name
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
ClinicalTrials.gov Identifier (if applicable)
NCT03602079
Clinical Trial Category (check all that apply)
  • Beyond First Line Therapy
  • Targeted Therapy
Study Center
Institution Name
The University of Texas MD Anderson Cancer Center
City
Houston
State
Texas
Zip Code
77030
Country
United States
List additional Institutions (include address, phone number, and website)
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States, 34232

Beth Israel Deaconess Medical Center Cancer Center
Boston, Massachusetts, United States, 02215

Karmanos Cancer Institute
Detroit, Michigan, United States, 48201

Clinical Research Alliance, Inc.
Lake Success, New York, United States, 11042

Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104

Providence Cancer Institute
Portland, Oregon, United States, 97213

Mary Crowley Cancer Research Centers – Medical City
Dallas, Texas, United States, 75230

South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas, United States, 78229

Virginia Cancer Specialist
Fairfax, Virginia, United States, 22031

Study Contacts
Principal Investigator
Jordi Rodon Ahnert, M.D., PhD
P.I. Phone
(713) 563-1930
P.I. Email
yjiang@mdanderson.org
List additional Principal Investigators (include phone number and email)
Virginia Cancer Specialist
Contact: Alexander Spira, MD, PhD,FACP 703-280-5390 Alexander.Spira@usoncology.com
Study Coordinator
Yunfang (Jenny) Jiang
Study Coordinator Phone
(713) 794-1751
Study Coordinator Email
yjiang@mdanderson.org
List additional Study Coordinators (include phone number and email)
Florida Cancer Specialists & Research Institute
Contact: Donna L Jones, BSN, RN, OCN, 941-377-9993

Beth Israel Deaconess Medical Center Cancer Center
Contact: Cassandra Cruz 617-975-7411 clcruz@bidmc.harvard.edu

Karmanos Cancer Institute
Contact: Valerie Davis 313-576-9370 davisv@karmanos.org

Clinical Research Alliance, Inc.
Contact: Colleen Kats ckats@researchcra.com

Stephenson Cancer Center
Contact: Dana Suters 405-271-8778 SCC-Clinical-Trials-Office@ouhsc.edu

Providence Cancer Institute
Contact: Christina Lopez 503-215-2614 Christina.Lopez4@providence.org

Mary Crowley Cancer Research Centers – Medical City
Contact: Amy Jordan 972-566-3000 referral@marycrowley.org

South Texas Accelerated Research Therapeutics, LLC (START)
Contact: Isabel Jimenez, RN, MSN 210-593-5265 isabel.jimenez@startsa.com

OVERVIEW – in layman’s terms (150 words max)
Study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Cycles will continue until disease progression or unacceptable toxicity.
Enrollment
102
Study Start Date
07/16/2018
Estimated Completion Date
01/10/2020
WordPress Image Lightbox Plugin
Back to Top